Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Oppenheimer Holdings upped their FY2017 earnings per share (EPS) estimates for Boston Scientific Corporation in a note issued to investors on Friday. Oppenheimer Holdings analyst S. Lichtman now anticipates that the medical equipment provider will post earnings per share of $1.25 for the year, up from their previous forecast of $1.24. Oppenheimer Holdings has a “Hold” rating and a $29.00 price target on the stock. Oppenheimer Holdings also issued estimates for Boston Scientific Corporation’s FY2018 earnings at $1.38 EPS.

A number of other brokerages have also recently commented on BSX. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific Corporation in a research note on Sunday. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a research note on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective (up previously from $29.00) on shares of Boston Scientific Corporation in a research note on Thursday, April 27th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $31.00 price objective (up previously from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Finally, Guggenheim reissued a “buy” rating on shares of Boston Scientific Corporation in a research note on Wednesday, April 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $30.00.

TRADEMARK VIOLATION WARNING: “Brokers Set Expectations for Boston Scientific Corporation’s FY2017 Earnings (NYSE:BSX)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/10/brokers-set-expectations-for-boston-scientific-corporations-fy2017-earnings-nysebsx-updated.html.

Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.27 EPS.

A number of hedge funds have recently modified their holdings of the company. Toronto Dominion Bank raised its stake in shares of Boston Scientific Corporation by 56.7% in the first quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock worth $9,150,000 after buying an additional 133,121 shares during the period. Koch Industries Inc. acquired a new stake in shares of Boston Scientific Corporation during the first quarter worth approximately $307,000. Bellevue Group AG raised its stake in shares of Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after buying an additional 22,000 shares during the period. Principal Financial Group Inc. raised its stake in shares of Boston Scientific Corporation by 1.7% in the first quarter. Principal Financial Group Inc. now owns 1,983,944 shares of the medical equipment provider’s stock worth $49,340,000 after buying an additional 33,763 shares during the period. Finally, Morgan Stanley raised its stake in shares of Boston Scientific Corporation by 63.8% in the first quarter. Morgan Stanley now owns 3,744,380 shares of the medical equipment provider’s stock worth $93,124,000 after buying an additional 1,458,906 shares during the period. Institutional investors and hedge funds own 91.96% of the company’s stock.

In related news, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the sale, the chief financial officer now directly owns 235,421 shares in the company, valued at $6,469,369.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $28.02, for a total value of $434,310.00. The disclosure for this sale can be found here. Insiders have sold 188,556 shares of company stock worth $5,155,752 over the last quarter. 0.74% of the stock is currently owned by corporate insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.